Solid Biosciences and Stoke Therapeutics Get Fresh Bullish Analyst Backing with Big Upside Targets
Truist restarts Solid Biosciences at Buy/$20. JPMorgan backs Stoke Therapeutics at Overweight/$40. Cash into 2028.
/ 185 items
#XY Analyst Up/Down↓
Immunocore’s Kimmtrak Anchors Growth as Pipeline Eyes Bigger Markets
Immunocore’s Kimmtrak hit ~$400M in 2025 sales with strong 2026 momentum. Solid cash, advancing Phase 3 trials, and Wall Street Buy ratings signal further upside.
What Makes Nuvation Bio a “Low-Risk, High-Reward” Stock According to Cantor
Cantor Fitzgerald starts coverage of Nuvation Bio at Overweight, citing a low-risk oncology story with upside from Ibtrozi and safusidenib.
Roth Capital Reiterates Buy Rating and $20 Target on CELZ as ADAPT Trial Completes Enrollment
CELZ-201 (Olastrocel) ADAPT trial fully enrolled and treated, including opioid patients. Clean safety profile and meaningful pain relief at 180 days; advancing toward RMAT review.
ProQR Therapeutics Gets BofA Buy Initiation After Positive AX-0810 Phase 1 Data
AX-0810 Phase 1 shows dose-dependent bile acid increases and no serious adverse events, delivering the first human proof of concept for ProQR’s Axiomer RNA editing.
Cantor Fitzgerald Starts Coverage of Milestone Pharmaceuticals with Overweight Rating and $3 Target
Cantor Fitzgerald initiates Overweight coverage on Milestone, citing Cardamyst’s strong PSVT launch potential and $250-300M peak sales outlook.